Originally published by our sister publication Specialty Pharmacy Continuum
An increase in rare/ultra-orphan treatments, along with a boom in cell and gene therapies and ambulatory infusion centers, are among developments to prepare for in the increasingly competitive specialty pharmacy market.
“Fifteen years ago, we were still figuring out specialty pharmacy itself and even a definition around it,” said Michael Baldzicki, the chief commercial officer at Polaris Specialty